Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Mousa Al Omari, Yousef Khader, Ali Shakir Dauod, Othman Ahmed Beni Yonis & Adi Harbi Mohammad Khassawneh. (2016) Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin. Journal of Drug Assessment 5:1, pages 29-33.
Read now
Read now
André J Scheen. (2013)
Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 363-377.
Read now
Read now
André J Scheen. (2013) Efficacy and safety of Jentadueto® (linagliptin plus metformin). Expert Opinion on Drug Safety 12:2, pages 275-289.
Read now
Read now
Elisa Guarino, Laura Nigi, Aurora Patti, Cecilia Fondelli & Francesco Dotta. (2012) Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 13:9, pages 1377-1384.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Mansur Shomali. (2011) Add-on therapies to metformin for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:1, pages 47-62.
Read now
Read now
Min-Koo Choi, Qing-Ri Jin, Sung-Hoon Ahn, Myung-Ae Bae & Im-Sook Song. (2010) Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters. Xenobiotica 40:12, pages 817-825.
Read now
Read now
Nasser Mikhail. (2008) Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vascular Health and Risk Management 4:6, pages 1221-1227.
Read now
Read now
Articles from other publishers (46)
Yan-Yu Lin, Shuen-Fu Weng, Chung-Huei Hsu, Chen-Ling Huang, Yu-Pei Lin, Min-Chun Yeh, A-Young Han & Yu-Shan Hsieh. (2022) Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus. Frontiers in Medicine 9.
Crossref
Crossref
Nikita Nirwan & Divya Vohora. (2022) Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice. Frontiers in Endocrinology 13.
Crossref
Crossref
Dong Han Won, Heejun Park, Jeong-Woong Seo, Sun Woo Jang, Eun-Sol Ha & Min-Soo Kim. (2022) Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl. International Journal of Pharmaceutics 623, pages 121927.
Crossref
Crossref
Arshiya Shadab, Ilma Hussain, Praveen Kumar Kandakurti, Marwan Ismail, Ahmed Luay Osman Hashim, Salah Eldin Omar Hussein & Altoum Abd Elgadir. (2022) Estimation of Serum Creatinine, Aspartate Aminotransferase, Alanine Transaminase, and Hemoglobin A1c% Levels among Diabetic Patients using Metformin/Dipeptide Peptidase-4 Inhibitor Combination and Insulin – A Cross-Sectional Study. Open Access Macedonian Journal of Medical Sciences 10:B, pages 959-965.
Crossref
Crossref
Seong-Joon Lee, Bok Seon Yoon, Ji Man Hong, Eun-Hye Joe & Jin Soo Lee. (2022) Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat. Experimental Neurology 348, pages 113922.
Crossref
Crossref
Wadhah Atef Salem, Ehab Farouk Elkady, Marwa Ahmed Fouad & Mohammad Abdul-Azim Mohammad. (2021) Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization. Journal of AOAC INTERNATIONAL 104:6, pages 1667-1680.
Crossref
Crossref
Dong Han Won, Heejun Park, Eun-Sol Ha, Hwan-Ho Kim, Sun Woo Jang & Min-Soo Kim. (2021) Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). International Journal of Pharmaceutics 605, pages 120838.
Crossref
Crossref
Ayodele T. Odularu & Peter A. Ajibade. (2021) Challenge of diabetes mellitus and researchers’ contributions to its control. Open Chemistry 19:1, pages 614-634.
Crossref
Crossref
AshokK Das, Pramod Gandhi, Banshi Saboo, Sanjay Reddy, Rajeev Chawla, AbdulHamid Zargar, Rajiv Kovil, Manoj Chawla, SK Sharma, Sunil Gupta, BM Makkar, Vinod Mittal, Soumik Goswami, SR Arvind, Shalini Jaggi, Sarita Bajaj & Sambit Das. (2021) Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion. Journal of Family Medicine and Primary Care 10:12, pages 4398.
Crossref
Crossref
Keisuke Ito, Takahiro Hosoya, Toyomi Yamazaki-Ito, Yuko Terada & Yasuaki Kawarasaki. (2021) Dipeptidyl peptidase IV inhibitory dipeptides contained in hydrolysates of green tea grounds. Food Science and Technology Research 27:2, pages 329-334.
Crossref
Crossref
Xin Wang, Jinhong Kang, Qing Liu, Tao Tong & Helong Quan. (2020) Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches. Current Pharmaceutical Design 26:39, pages 4992-5001.
Crossref
Crossref
Ankit Gupta, Christian K. Narkowicz, Hayder A. Al-Aubaidy, Herbert F. Jelinek, David S. Nichols, John R. Burgess & Glenn A. Jacobson. (2020) Phytosterol supplements do not inhibit dipeptidyl peptidase-4. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14:5, pages 1475-1478.
Crossref
Crossref
Hongliang Li, Mi Seon Seo, Jin Ryeol An, Hee Seok Jung, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Young Min Bae, Sung Hun Na & Won Sun Park. (2019) Dipeptidyl peptidase-4 inhibitor sitagliptin induces vasorelaxation via the activation of Kv channels and PKA. Toxicology and Applied Pharmacology 384, pages 114799.
Crossref
Crossref
Rubiya Khursheed, Sachin Kumar Singh, Sheetu Wadhwa, Bhupinder Kapoor, Monica Gulati, Rajan Kumar, Arya Kadukkattil Ramanunny, Ankit Awasthi & Kamal Dua. (2019) Treatment strategies against diabetes: Success so far and challenges ahead. European Journal of Pharmacology 862, pages 172625.
Crossref
Crossref
Bo Ahrén. (2019) DPP-4 Inhibition and the Path to Clinical Proof. Frontiers in Endocrinology 10.
Crossref
Crossref
Hiroshi Takahashi, Rimei Nishimura, Daisuke Tsujino & Kazunori Utsunomiya. (2018) Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study. Journal of Diabetes Investigation 10:3, pages 714-722.
Crossref
Crossref
Sojeong Jin, Sowon Lee, Ji-Hyeon Jeon, Hyuna Kim, Min-Koo Choi & Im-Sook Song. (2019) Enhanced Intestinal Permeability and Plasma Concentration of Metformin in Rats by the Repeated Administration of Red Ginseng Extract. Pharmaceutics 11:4, pages 189.
Crossref
Crossref
Johan Farngren, Margaretha Persson & Bo Ahrén. (2018) Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 20:8, pages 1911-1920.
Crossref
Crossref
Ramswaroop Jawaharlal & Pravin G. Maske. (2017) A PROSPECTIVE STUDY OF ADDITION OF SITAGLIPTIN TO METFORMIN VERSUS METFORMIN ALONE IN TYPE 2 DIABETES MELLITUS PATIENTS. Journal of Evidence Based Medicine and Healthcare 4:73, pages 4327-4330.
Crossref
Crossref
Qin Fu, Qian Shi, Toni M. West & Yang K. Xiang. (2017) Cross-Talk Between Insulin Signaling and G Protein–Coupled Receptors. Journal of Cardiovascular Pharmacology 70:2, pages 74-86.
Crossref
Crossref
Fuu-Jen Tsai, Tsung-Jung Ho, Chi-Fung Cheng, Xiang Liu, Hsinyi Tsang, Ting-Hsu Lin, Chiu-Chu Liao, Shao-Mei Huang, Ju-Pi Li, Cheng-Wen Lin, Jaung-Geng Lin, Jung-Chun Lin, Chih-Chien Lin, Wen-Miin Liang & Ying-Ju Lin. (2017) Effect of Chinese herbal medicine on stroke patients with type 2 diabetes. Journal of Ethnopharmacology 200, pages 31-44.
Crossref
Crossref
Helena Pelantová, Martina Bugáňová, Martina Holubová, Blanka Šedivá, Jana Zemenová, David Sýkora, Petra Kaválková, Martin Haluzík, Blanka Železná, Lenka Maletínská, Jaroslav Kuneš & Marek Kuzma. (2016) Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Molecular and Cellular Endocrinology 431, pages 88-100.
Crossref
Crossref
Abdulrahman S. Alanazi. (2015) Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Saudi Pharmaceutical Journal 23:6, pages 603-613.
Crossref
Crossref
Jason Seewoodhary, Stephen Phooi Yew Wong & Kaharanthilaka Poojanie Ekanayake. (2015) New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?. Practical Diabetes 32:8, pages 291-296a.
Crossref
Crossref
M. P. Yavropoulou, M. Pikilidou, K. Kotsa, A. Michopoulos, E. Papakonstantinou & J. G. Yovos. (2015) Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. Journal of Diabetes & Metabolic Disorders 14:1.
Crossref
Crossref
Asima Zia, Attya Bhatti, Peter John & Aysha Karim Kiani. (2015) Data interpretation: deciphering the biological function of Type 2 diabetes associated risk loci. Acta Diabetologica 52:4, pages 789-800.
Crossref
Crossref
Bo Ahrén. (2015) Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?. Diabetologia 58:8, pages 1740-1744.
Crossref
Crossref
Vu Thi Tuyet Lan, Keisuke Ito, Masumi Ohno, Takayasu Motoyama, Sohei Ito & Yasuaki Kawarasaki. (2015) Analyzing a dipeptide library to identify human dipeptidyl peptidase IV inhibitor. Food Chemistry 175, pages 66-73.
Crossref
Crossref
Hyun-Uk Jeong, Hee Eun Kang, Sang-Zin Choi, Miwon Son, Im-Sook Song & Hye Suk Lee. (2014) Evaluation of drug--drug interaction potential between DA-9801 and metformin. Journal of Pharmaceutical Investigation 44:6, pages 401-409.
Crossref
Crossref
R. E. Pratley, P. Fleck & C. Wilson. (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism 16:7, pages 613-621.
Crossref
Crossref
D. Wu, L. Li & C. Liu. (2014) Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, Obesity and Metabolism 16:1, pages 30-37.
Crossref
Crossref
Tae Jung Oh, Ji Yon Shin, Gyeong Hoon Kang, Kyong Soo Park & Young Min Cho. (2013) Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. Experimental & Molecular Medicine 45:7, pages e30-e30.
Crossref
Crossref
J. Vora, S.C. Bain, T. Damci, G. Dzida, P. Hollander, L.F. Meneghini & S.A. Ross. (2013) Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes. Diabetes & Metabolism 39:1, pages 6-15.
Crossref
Crossref
C. F. Deacon, E. Mannucci & B. Ahrén. (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes, Obesity and Metabolism 14:8, pages 762-767.
Crossref
Crossref
V. Fonseca, T. Zhu, C. Karyekar & B. Hirshberg. (2012) Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes, Obesity and Metabolism 14:4, pages 365-371.
Crossref
Crossref
A.J. Scheen. (2012) DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes & Metabolism 38:2, pages 89-101.
Crossref
Crossref
E. Bosi, G. C. Ellis, C. A. Wilson & P. R. Fleck. (2011) Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obesity and Metabolism 13:12, pages 1088-1096.
Crossref
Crossref
Atsushi Tajima, Takashi Hirata, Kazuo Taniguchi, Yukiko Kondo, Sota Kato, Masako Saito-Hori, Tsuyoshi Ishimoto & Koji Yamamoto. (2011) Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes. Life Sciences 89:17-18, pages 662-670.
Crossref
Crossref
Rupa Ahluwalia & Jiten Vora. (2011) Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Therapy 2:3, pages 146-161.
Crossref
Crossref
Bo Ahrén. (2011) GLP-1 for type 2 diabetes. Experimental Cell Research 317:9, pages 1239-1245.
Crossref
Crossref
Seung Jin Han, Sung-E. Choi, Yup Kang, Jong Gab Jung, Sang-A. Yi, Hae Jin Kim, Kwan Woo Lee & Dae Jung Kim. (2011) Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Research and Clinical Practice 92:2, pages 213-222.
Crossref
Crossref
Baptist Gallwitz. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
53
74
.
Baptist Gallwitz. (2010) The evolving place of incretin-based therapies in type 2 diabetes. Pediatric Nephrology 25:7, pages 1207-1217.
Crossref
Crossref
C. Filozof & J.-F. Gautier. (2010) A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabetic Medicine 27:3, pages 318-326.
Crossref
Crossref
Baptist Gallwitz. (2010) DPP-4-Inhibitoren in der Klinik. Therapie ohne Hypoglykämie-Gefahr. Pharmazie in unserer Zeit 39:2, pages 114-118.
Crossref
Crossref
Kun Yang, Hongjun Bai, Qi Ouyang, Luhua Lai & Chao Tang. (2008) Finding multiple target optimal intervention in disease‐related molecular network. Molecular Systems Biology 4:1.
Crossref
Crossref